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Myeloid-derived vascular endothelial growth factor (VEGF) has been proposed to drive ocular neovascu-
larization (ONV),1–4 a pathological feature common to lead-
ing causes of blindness, including retinopathy of prematurity 
in infants, proliferative diabetic retinopathy in the work-
ing population, and age-related macular degeneration in the 
elderly.5 In mice with oxygen-induced retinopathy (OIR), a 
model of retinopathy of prematurity, VEGF-expressing mac-
rophages are recruited to sites of retinal neovascularization 
(RNV), and clodronate-induced or genetic macrophage deple-
tion reduces RNV, raising the possibility that myeloid-derived 
VEGF promotes RNV.3,6,7 In laser-induced choroidal neovas-
cularization (CNV), a mouse model of age-related macular 
degeneration–associated neovascularization, peak VEGF 
expression correlates with maximal myeloid infiltration, 
and clodronate-induced macrophage depletion reduces both 
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VEGF levels and CNV area.1 The absence of VEGF-producing 
CCR2+ macrophages also reduces CNV area.2 Human CNV 
lesions have also been reported to contain VEGF-expressing 
macrophages, which were suggested to cooperate with 
VEGF-expressing retinal pigment epithelium (RPE) to drive 
angiogenesis.8 These findings raised the possibility that 
myeloid-derived VEGF also promotes CNV. However, others 
contested that myeloid-derived VEGF enhances CNV.9 The 
significance of myeloid-derived VEGF in ONV, therefore, 
remains controversial. Moreover, the importance of myeloid-
derived hypoxia-inducible factors, HIF1α and HIF2α, has not 
yet been defined for ONV, even though they regulate VEGF 
expression,10 have been implicated in myeloid-mediated 
angiogenesis in various tissues11 and are expressed in OIR 
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Objective—Ocular neovascularization (ONV) is a pathological feature of sight-threatening human diseases, such as diabetic 
retinopathy and age-related macular degeneration. Macrophage depletion in mouse models of ONV reduces the formation 
of pathological blood vessels, and myeloid cells are widely considered an important source of the vascular endothelial 
growth factor A (VEGF). However, the importance of VEGF or its upstream regulators hypoxia-inducible factor-1α 
(HIF1α) and hypoxia-inducible factor-2α (HIF2α) as myeloid-derived regulators of ONV remains to be determined.
Approach and Results—We used 2 mouse models of ONV, choroidal neovascularization and oxygen-induced retinopathy, to 
show that Vegfa is highly expressed by several cell types, but not myeloid cells during ONV. Moreover, myeloid-specific 
VEGF ablation did not reduce total ocular VEGF during choroidal neovascularization or oxygen-induced retinopathy. In 
agreement, the conditional inactivation of Vegfa, Hif1a, or Epas1 in recruited and resident myeloid cells that accumulated 
at sites of neovascularization did not significantly reduce choroidal neovascularization or oxygen-induced retinopathy.
Conclusions—The finding that myeloid cells are not a significant local source of VEGF in these rodent models of ONV 
suggests that myeloid function in neovascular eye disease differs from skin wound healing and other neovascular 
pathologies.  (Arterioscler Thromb Vasc Biol. 2016;36:19-24. DOI: 10.1161/ATVBAHA.115.306681.)
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and CNV models.12,13 To test the prevailing idea in the cur-
rent literature that myeloid VEGF is nonredundant with other 
VEGF sources in ONV, we used conditional mouse knockout 
models to target Vegfa and its upstream regulators, Hif1a and 
Epas1 (Hif2a), in myeloid cells, and analyzed the effects of 
their deletion on RNV and CNV. Unexpectedly, we found that 
myeloid-derived HIFs and VEGF are dispensable ONV, sug-
gesting that they do not present useful targets for therapy of 
ocular disease.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Briefly, animal procedures were conducted with ethical approval 
under institutional and UK Home Office guidelines using Lysm+/Cre; 
Hif1afl/fl, Lysm+/Cre;Epas1fl/fl and Lysm+/Cre;Vegfafl/fl11,14,15, Tie2-
Cre;Vegfafl/fl,16 Vegfa+/LacZ, Rosa26Yfp, and Rosa26mT/mG17–19 mice in 
OIR20 and CNV21 assays for gene expression, Cre recombination and 
ONV assays.
Results
We induced OIR or CNV in Vegfa+/LacZ mice, previously shown 
to faithfully report Vegfa gene expression in macrophages and 
other cells types.17,22 X-gal staining of eye sections indicated 
prominent Vegfa expression in the RPE, inner nuclear layer, 
and retinal ganglion cell layer on postnatal day (P) 17 in the 
OIR and on day (D) 3 postlasering in the CNV model, when 
VEGF levels and myeloid infiltration peak,1,23 but Vegfa expres-
sion was below the detection limit in IBA1+ F4/80+ microglia/
macrophages (Figure 1A and 1B). Vegfa expression was also 
undetectable in YFP+ IB4+ myeloid cells by in situ hybridiza-
tion on D3 after lasering Lysm+/Cre eyes carrying the Rosa26Yfp 
reporter to identify myeloid cells, even though other cell types 
strongly expressed Vegfa (Figure 1C). These findings suggest 
that, compared with other ocular cell types, myeloid cells are 
unlikely a significant local source of VEGF for ONV.
OIR retinas from Lysm+/Cre;Rosa26Yfp myeloid reporter 
mice accumulated YFP+ myeloid cells in both avascu-
lar and vascularized areas at P14, before the onset of RNV 
(Figure 1D–1F). By P17, YFP+ myeloid cells had accumu-
lated near neovascular tufts (Figure 1D, 1E, and 1G). We 
also observed YFP-expressing myeloid cells at sites of laser 
injury in Lysm+/Cre;Rosa26Yfp eyes on D3 postlasering, the 
onset of CNV (Figure 1H). Flow cytometry analysis of D3 
Lysm+/Cre;Rosa26mT/mG choroid/RPE complex showed efficient 
recombination in infiltrating CD11b+ myeloid cells, particu-
larly neutrophils and inflammatory monocytes/macrophages 
(Figure 1I). Importantly, the LysmCre allele did not affect the 
size of avascular or neovascular areas on P17 (Lysm+/Cre: 
6.9±1.9%; Lysm+/+: 7.6±2.8%; mean±SD, n=15, P>0.05) or 
CNV lesions on D7 or D14 postlasering (Figure 1J). Lysm+/Cre 
is therefore a suitable tool to target genes in myeloid cells 
recruited to sites of ONV.
Next, we examined Lysm+/Cre;Vegfafl/fl mice, which are 
deficient in myeloid cell–derived Vegfa and were previ-
ously shown to have reduced pathological angiogenesis in 
wound healing and cancer models.22,24 Lysm+/Cre;Vegfafl/fl 
mice appeared healthy as previously reported and had nor-
mal retinal angiogenesis (Figure IA in the online-only Data 
Supplement). YFP-expressing splenic myeloid cells showed 
efficient Vegfa gene targeting and, accordingly, Vegfa mRNA 
was reduced in mutant compared with control YFP+ splenic 
myeloid cells (Figure 2A and 2B). Nevertheless, myeloid 
VEGF deletion did not alter overall VEGF protein or mRNA 
levels in the P17 OIR retina or D3 postlasering RPE/choroid 
(Figure 2C and 2D). In agreement, the size of the central 
avascular and neovascular areas in P17 OIR retina and D7 
and D14 CNV lesions was similar in Lysm+/Cre;Vegfafl/fl mice 
and controls (Figure 2E–2F′). Moreover, myeloid VEGF 
depletion did not affect CD11b+ cell recruitment to the RPE/
choroid on D3 postlasering (Figure 2G).
We also examined Tie2-Cre;Vegfafl/fl mice because Tie2-Cre 
targets yolk sac–derived tissue-resident macrophages more 
efficiently than LysmCre/+, including microglia in the brain25,26 
and retina (Figure 2H and 2I). Tie2-Cre;Vegfafl/fl mutant mice 
are healthy, and despite targeting of Vegfa in hematopoietic 
and endothelial cells, have no obvious vascular defects and 
only develop vascular dysfunction in old age.16,27 In agree-
ment, angiogenesis and the density of resident myeloid cells 
were similar in mutant and control postnatal retinas (Figure 
IB and IC in the online-only Data Supplement). Moreover, 
the size of the central avascular and neovascular areas in P17 
OIR retina and CNV lesions was not significantly different 
between mutants and controls (Figure 2J–2K′). These data 
suggest that VEGF expression by resident microglia/macro-
phages does not explain the lack of angiogenesis defects in 
mice with LysmCre-mediated targeting of VEGF in myeloid 
cells. Myeloid cell–derived VEGF is therefore dispensable for 
retinal angiogenesis and pathological ONV.
Because HIFs promote the expression of Vegfa and other 
hypoxia-induced proangiogenic molecules,10 we also targeted 
the genes encoding HIF1α and HIF2α in myeloid cells with 
LysmCre. Targeting of Hif1a, Epas1, or both did not affect reti-
nal vascular development, despite efficient Lysm+/Cre-mediated 
Hif1a or Epas1 deletion in myeloid cells (Figure IIA and IIB 
in the online-only Data Supplement). Moreover, the size of 
the central avascular and neovascular areas on P17 after OIR 
(Figure IIIA and IIIB in the online-only Data Supplement) and 
D7 and D14 CNV lesions (Figure IIIC and IIID in the online-
only Data Supplement) were similar in controls and mutants 
for Hif1a, Epas1, or both. The recruitment of myeloid cells, 
including individual subpopulations, to ONV sites was also not 
impaired after LysmCre-mediated targeting of Hif1a, Epas1, or 
both (Figure IIIE and IIIE′ in the online-only Data Supplement).
Discussion
Nonmyeloid VEGF is thought to promote RNV because reti-
nal ganglion cells28,29 and Mueller cells30–32 are abundant VEGF 
Nonstandard Abbreviations and Acronyms
CNV choroidal neovascularization
HIF hypoxia-inducible factor
OIR oxygen-induced retinopathy
ONV ocular neovascularization
RNV retinal neovascularization
VEGF vascular endothelial growth factor A
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sources in the OIR model. Moreover, it was shown that the dele-
tion of Mueller cell–derived VEGF in a mouse model of diabe-
tes mellitus reduces RNV.33 Furthermore, RPE-derived VEGF 
has been implicated in CNV in both mice34–36 and patients,8 
and HIF1α depletion in RPE cells impairs VEGF expression 
and reduces CNV in mice.36,37 VEGF expression and myeloid 
cell depletion studies have been interpreted as evidence that 
myeloid-derived VEGF provides an additional, nonredundant 
source of VEGF for both RNV and CNV.1–4,8 However, our 
studies show that myeloid expression of VEGF or its upstream 
regulators, HIF1α and HIF2α, is not necessary for ONV in 
rodent models of OIR and CNV. Previous studies deducing 
a role for myeloid-derived VEGF in ONV by correlating the 
phenotype caused by myeloid cell depletion with changes in 
VEGF levels1–3 may, therefore, have only identified an indirect 
association of both pathological parameters in eye disease. 
For example, myeloid cells may influence ONV indirectly by 
stimulating VEGF production by other cell types, such as the 
Figure 1. Myeloid cells accumulate at sites of ocular neovascularization (ONV), but are not a significant source of Vegfa. A–C, Vegfa 
expression in ONV. X-gal staining (left) followed by labeling for IBA1, F4/80, and IB4 (middle) of Vegfa+/LacZ eyes on P17 in the oxygen-
induced retinopathy (OIR) model (A) or on D3 after laser injury (B). X-gal was pseudocolored orange and retinal pigment epithelium (RPE) 
pigment gray for overlay with fluorescent signals (right). Vegfa in situ hybridization (C) of an Lysm+/Cre;Rosa26Yfp eye section on D3 after 
laser injury, shown at higher magnification on the right. Bottom, C, The Vegfa signal was inverted into the blue channel for overlay with 
YFP and IB4 staining. Arrowheads indicate examples of IB4+ YFP+ myeloid cells and clear arrowheads indicate their lack of Vegfa expres-
sion. D and E, Retinal flatmounts (D) and sections (E) of Lysm+/Cre;Rosa26Yfp OIR retinas labeled for IB4 and YFP on P14 (top) or P17 (bot-
tom), counterstaind with 4′,6-diamidino-2-phenylindole (DAPI). Examples of quiescent vessels (clear arrows) and YFP+ IB4+ myeloid cells 
(arrowheads) associated with neovascular tufts (arrows) are indicated. Areas indicated by squares are shown at higher magnification in 
adjacent panels (D). F and G, Quantification of YFP+ cells in the vascular plexus, avascular (AV) and neovascular (NV) areas of Lysm+/Cre; 
 Rosa26Yfp retinal flatmounts on P14 (F) and P17 (G) in the OIR model; n≥5 mice each, ***P<0.001 for NV vs AV or vascular plexus, 1-way 
ANOVA. H, YFP+ myeloid cells in Lysm+/Cre;Rosa26Yfp adult eye sections on D3 after laser injury. I, Flow cytometric analysis of the choroid/
RPE shows reporter activation in CD11b+ myeloid cells and myeloid subsets in Lysm+/Cre;Rosa26mT/mG eyes on D3 after laser injury; n≥5 
each. J, Similar lesion area in Lysm+/Cre and Lysm+/+ mice after laser injury; n≥11 mice each, P>0.05, t test. a indicates artery; CNV, choroi-
dal neovascularization; INL, inner nuclear layer; ns, not significant; ONL, outer nuclear layer; RGC, retinal ganglion cell layer; and v, vein. 
Scale bars, 50 μm (A, B, C, E, and H), 200 μm (D).
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Figure 2. Myeloid-derived Vegfa does not significantly contribute to the total vascular endothelial growth factor (VEGF) pool or ocular neovas-
cularization. (A and B) Polymerase chain reaction detection of Vegfa gene (A) and mRNA recombination (B) in YFP+ splenocytes in Vegfafl/fl; 
Lysm+/Cre;Rosa26Yfp mutants (A and B) and Vegfa+/fl;Lysm+/Cre;Rosa26Yfp controls (B); n≥3 mice each, P<0.05, t test. (C and D) VEGF protein 
levels (C) in the P17 oxygen-induced retinopathy (OIR) retina (left) and the retinal pigment epithelium (RPE)/choroid on D3 after laser injury 
(right) and Vegfa mRNA (mean fold change relative to Actb, (D) in the RPE/choroid on D3 after laser injury in Lysm+/Cre;Vegfafl/fl mice and 
control littermates; mean±SD, n≥3 each; P>0.05, t test. (E–E″) IB4 staining (E) of P17 OIR Lysm+/Cre;Vegfafl/fl and control retina. E′, Total 
retina, avascular (AV) and neovascular (NV) areas are rendered gray, yellow, and red, respectively. E″, Proportion of central AV and NV 
areas; mean±SD, n≥6 each; P>0.05, t test. F–G, D14 angiograms (F) and choroidal neovascularization (CNV) lesion area on D7 and D14 
(F′) and percentage of CD11b+ cells in choroid/RPE on D3 after laser injury (G) of Lysm+/Cre;Vegfafl/fl and control mice; mean±SD, n≥4 each; 
P>0.05, t test. H and I, Wholemount retina staining for IB4, F4/80, and YFP shows recombination in microglia in Lysm+/Cre;RosaYfp mice (H) 
and in most microglia and endothelium in Tie2-Cre;RosaYfp mice (I). J–J″, IB4 staining (J) of P17 OIR Tie2-Cre;Vegfafl/fl and control retina. 
J′, Total retina, AV, and NV areas are rendered gray, yellow, and red, respectively. J″, Proportion of central AV and NV areas in Tie2-
Cre;Vegfafl/fl and control P17 OIR retina stained with IB4; mean±SD, n≥5 mice each; P>0.05, t test. K and K′, D14 angiograms (K) and 
quantification of CNV lesion area on D7 and D14 after laser injury (K′) in Tie2-Cre;Vegfafl/fl mice and littermate controls; n≥5 mice each, 
P>0.05, t test. Scale bars, 1 mm (E, F, J, and K), 200 μm (H and I).
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neural or glial sources previously implicated in ONV. Myeloid 
cells have also been found to influence angiogenesis by VEGF-
independent mechanisms, for example, by acting as cellular 
chaperones to promote endothelial tip cell fusion during vascu-
lar development26 or by producing proangiogenic factors differ-
ent from VEGF during tumor vascularization.38 The molecular 
mechanisms of inflammatory cell modulation of neovascular 
eye disease, therefore, differs significantly from nonocular dis-
ease models, in which myeloid-derived VEGF is nonredundant 
with other VEGF sources to promote pathological angiogen-
esis, even when nonmyeloid VEGF is abundant, for example, 
during tumor vascularization or in skin wound healing.22,24
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Previous work inferred from correlative studies that myeloid-derived vascular endothelial growth factor drives ocular neovascularization via 
induction of angiogenesis. Unexpectedly, we find that Vegfa is not expressed at significant levels by myeloid cells in the eye, and, accord-
ingly, myeloid-derived vascular endothelial growth factor and its upstream regulator hypoxia-inducible factors are not required for ocular 
neovascularization. Our work implies organ-specific mechanisms by which myeloid cells regulate angiogenesis because myeloid cells do 
provide a significant and nonredundant source of vascular endothelial growth factor to promote pathological angiogenesis in other settings, 
such as skin wound healing and cancer. Moreover, our work suggests that understanding the role of myeloid cells in ocular angiogenesis 
requires focus on pathways unrelated to vascular endothelial growth factor or hypoxia-inducible factors.
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